menu

Uncovering the Results of the DELIVER Trial

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Uncovering the Results of the DELIVER Trial

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School. 

Facebook Comments

Schedule7 Dec 2022